SCHEMBL6489333

SCHEMBL6489333

CC(C)c1ccc(-c2ccc(F)cc2)c(C(=O)Nc2ccc(NCCc3ccccn3)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.53
TAS1R1 Q7RTX1 1/20 0.53
MAOB P27338 1/20 0.49
KDM4E B2RXH2 2/20 0.48
MEN1 O00255 2/20 0.48
MAPT P10636 2/20 0.48
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
GAA P10253 1/20 0.48
HTT P42858 2/20 0.46
NPC1 O15118 2/20 0.45
CTNNB1 P35222 1/20 0.45
TCF7L2 Q9NQB0 1/20 0.45
HTR2C P28335 1/20 0.44
HTR7 P34969 1/20 0.44
NAMPT P43490 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.43
NR3C1 P04150 1/20 0.42
GCGR P47871 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489631 0.94 TAS1R3 (0.56) TAS1R3TAS1R1MAOBKDM4EMEN1
SCHEMBL6489185 0.93 TAS1R3 (0.53) TAS1R3TAS1R1MAOBMAPTL3MBTL1
SCHEMBL6489909 0.90 TAS1R3 (0.51) TAS1R3TAS1R1MAOBMEN1MAPT
SCHEMBL6487583 0.90 HTT (0.52) MAOBKDM4EMEN1MAPTKMT2A
SCHEMBL6490703 0.89 NPC1 (0.48) TAS1R3TAS1R1MAOBKDM4EMEN1
SCHEMBL6487331 0.88 MEN1 (0.49) MAOBKDM4EMEN1MAPTKMT2A
SCHEMBL6490637 0.88 CTNNB1 (0.54) MAOBKDM4EMEN1MAPTKMT2A
SCHEMBL6788390 0.88 TAS1R3 (0.61) TAS1R3TAS1R1MAOBKDM4EMEN1
SCHEMBL6490335 0.87 CNR1 (0.52) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL6502209 0.86 CTNNB1 (0.50) MAOBKDM4EMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 TAS1R3 4388/4885TAS1R1 3270/4885MAOB 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.